Felipe de Arriba de la Fuente

Profesor Asociado

Universidad de Murcia

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (10)

Verónica González-Calle

University Hospital of Salamanca

SPAIN

View details

Iria Vázquez Urio

Profesora Ayudante Doctor

Public University of Navarre

SPAIN

View details

José María Bellón Cano

Instituto de Investigación Sanitaria Gregorio Marañón

SPAIN

View details

Cristina Pérez Ruiz

Universidad de Navarra

SPAIN

View details

Jesus F. San Miguel

SPAIN

View details

Cirino Botta

Assistant Professor of Hematology

University of Palermo

ITALY

View details

MJ Calasanz

Full Professor of Genetics

Universidad de Navarra

SPAIN

View details

Enrique M. Ocio

SPAIN

View details

Albert Oriol

Institut Català d'Oncologia

SPAIN

View details

Pierpaolo Correale

Oncologist with a High Professional Thoracic Oncology Assignment

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Felipe de Arriba de la Fuente

Research Interests

Explore related searches

Contact this professor

Articles (16)

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED BY RESIDUAL DISEASE STATUS IN MYELOMA

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies

Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma.

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New.

Collaborators (10)

Verónica González-Calle

Iria Vázquez Urio

José María Bellón Cano

Cristina Pérez Ruiz

Jesus F. San Miguel

Cirino Botta

MJ Calasanz

Enrique M. Ocio

Albert Oriol

Pierpaolo Correale

Make your next move.